BOCA RATON, Fla., Jan. 12, 2007 (PRIME NEWSWIRE) -- StockMarketNewsAlert.com issues New Trade Alert for Point Therapeutics, Inc. (Nasdaq:POTP). According to M. D'Alonzo at First Equity Group Inc., recent news flow from the company has been very positive: "The company provided preliminary results from the Company's open-label Phase 2 trial of talabostat plus gemcitabine in patients with metastatic pancreatic cancer (Stage IV) who have not received prior chemotherapy."
Of the 21 evaluable patients who entered the study at least six months ago, ten (48%) have survived more than six months. In addition, 31 patients are currently evaluable for tumor response. To date, three patients (9.7%) have demonstrated a clinical response to treatment, including one complete response and two partial responses. One patient with metastatic disease to the liver experienced a complete response to treatment -- defined as the complete disappearance of tumor. Thus far, no unexpected toxicities have been seen in the trial that would prevent the Company from continuing to study talabostat in combination with gemcitabine.
The Phase 2 study is a single-arm, two-stage study in up to 60 evaluable patients with metastatic pancreatic cancer. The primary clinical endpoint is six-month survival. Secondary study endpoints include overall survival, progression-free survival, quality of life, and performance status. The Phase 2 study protocol called for an interim assessment before advancing the study to completion. Based on the preliminary six-month survival results and the responses seen to date, the Company has decided to advance the study to completion. Final results from the study are expected mid-year 2007.
"Metastatic pancreatic cancer represents a significant unmet medical need as there are limited treatment options available for patients. I am pleased with the activity seen to date in this trial, especially with an oral agent, and look forward to evaluating further data as it becomes available," said Dr. Yagnesh Oza, MD, Medical Director at the Center for Comprehensive Cancer Care in Mt. Vernon, IL and an investigator in the study.
"It's encouraging to see Point's preclinical work potentially translating into clinical benefits for patients," said Dr. George Demetri, a member of Point's Clinical Advisory Board and Director of the Ludwig Center at Dana-Farber/Harvard. "Point has demonstrated preclinically that talabostat is a potent inhibitor of fibroblast activation protein (FAP), an enzyme that is highly expressed in pancreatic cancer and is believed to promote tumor growth. In addition, preclinical work combining talabostat with gemcitabine has also demonstrated encouraging results. I believe these factors make pancreatic cancer a promising target for the study of talabostat," concluded Dr. Demetri.
About Pancreatic Cancer:
According to the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2006 alone, 33,730 new cases of pancreatic cancer were diagnosed and 32,300 people died of the disease. The main reason for the poor prognosis of pancreatic cancer is that patients usually have no symptoms until the cancer has spread to other organs, and, as a result, very few of these cancers are found early. Patients with Stage IV disease have the most advanced form of pancreatic cancer, which includes metastatic disease to distant organ(s).
About Point Therapeutics, Inc.:
Point is a Boston-based biopharmaceutical company which is currently studying its lead product candidate, talabostat, in two Phase 3 double blind placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.
Certain statements contained herein are not strictly historical and are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements with respect to the company's clinical development programs and the timing of initiation and completion of its clinical trials. Forward-looking statements are statements that are not historical facts, and can be identified by, among other things, the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "projects," "should," "seeks," "plans," "schedules to," "anticipates" or "intends" or the negative of those terms, or other variations of those terms of comparable language, or by discussions of strategy or intentions. A number of important factors could cause actual results to differ materially from those projected or suggested in the forward-looking statement, including the risk factors described in Point's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006, and from time to time in Point's other reports filed with the Securities and Exchange Commission.
About StockMarketNewsAlert.com
StockMarketNewsAlert.com was developed solely for experienced, risk-tolerant investors. Subscribers to StockMarketNewsAlert.com receive daily market commentary reports for select companies trading on various markets. Sophisticated investors are also able to receive for free, select, rare research reports and investor kits on up and coming emerging companies while they are still not widely known.
StockMarketNewsAlert.com's (SMNA) primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small- and micro-cap companies. StockMarketNewsAlert.com is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. SMNA's goal is to feature equity investments in micro- or small-capitalization companies that have the potential for long-term appreciation. SMNA provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. StockMarketNewsAlert.com offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.stockmarketnewsalert.com.
Let Stock Market News Alert help advertise for your company using our effective awareness campaigns. If you're interested in telling your story, we can help. Contact us at info@stockmarketnewsalert.com. SMNA's e-mail alert service is free to those investors who sign up on the SMNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. To subscribe to this free service, visit the Stock Market News Alert home page at http://www.stockmarketnewsalert.com and select the "sign up" button.
Information contained herein is the opinion of StockMarketNewsAlert.com and is intended to be used strictly for informational purposes. You should be aware that SMNA attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, SMNA does, at times, rely on the accuracy of information supplied to it by the companies, which are the subject of SMNA's analyses and/or parties related to those companies. SMNA also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
SMNA, because it relies on information supplied by various third parties, disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of an SMNA analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an SMNA opinion, recommendation or analysis.
Information regarding companies, which SMNA has an opinion upon, is normally available from many sources, including the subject company's filings with the SEC and various press releases issued by the company.
All material herein is information supplied by the company or other sources believed to be reliable. The information contained herein is not guaranteed by First Equity Group, Inc. to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this profile have approved the statements made in this profile. This profile contains forward-looking statements that involve risks and uncertainties. Statements in this press release about the company's future expectations other than historical facts, are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Act of 1934, as that term is defined in the Private Securities Litigation Reform Act of 1995. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements. Such "forward-looking statements" are subject to risks and uncertainties set forth from time to time in the company's SEC reports that could cause results to differ materially from those expressed or implied include, but are not limited to, the results of future tests and the availability of funding for additional research and development. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. First Equity Group is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.stockmarketnewsalert.com. First Equity Group's affiliates, officers, directors, and employees may also have bought or may buy the shares discussed in this profile and may profit in the event those shares rise in value. First Equity Group does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.